Humana rises as TD Cowen upgrades the insurer to Buy
What is behind the stock move?
TD Cowen upgraded Humana to Buy from Hold and increased its price target from $430 to $485 on November 20. The upgrade adds a positive valuation signal while investors assess whether the insurer can rebuild profit margins. Humana’s November 6 management update identified insurance pricing and its 2028 margin target as key parts of that recovery. The December 10 investor update is the next scheduled checkpoint.
Latest company research
Humana rose 4.81% during trading on November 20 after TD Cowen upgraded the insurer to Buy from Hold.
- TD Cowen raised its price target to $485 from $430. This is an analyst opinion about value, not a guaranteed future share price.
- Humana sells health insurance and provides primary care, pharmacy and home-health services. Keeping medical costs below insurance premiums is central to its profit recovery.
- In its November 6 update, Humana targeted at least a 3% pretax margin in individual Medicare Advantage by 2028. That means retaining at least $3 before tax for every $100 of revenue in that business.
- The company said its 2027 insurance pricing should help that recovery. The investor question is whether better pricing can offset medical costs without losing too many members.
- Medical spending and government payment rules remain important risks. A stronger analyst rating does not remove those pressures.
- The November 19 closing price was $380 below the 20-day and 50-day averages. The rebound needs follow-through to repair that recent weakness.
Watch the December 10 investor update for progress toward the company’s 2028 goals. The charts show the completed November 19 session; November 20 trading is separate.
Financials and technicals
Charts through Nov 19, 2026. The session move above may reflect later news.
Technical setup and risks
Historical support is around $373–380 and resistance around $392–394, based on November 19 prices. Holding above that high would improve the rebound; losing $373 would weaken it. These are scenarios, not price promises.
AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.